Boardroom Alpha
Boardroom Alpha
ANTX · Additional Proxy Materials (DEFA14A) · Filed April 22, 2026

An2 Therapeutics Inc — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
April 22, 2026
Ticker
ANTX
Accession
0001193125-26-170321
Boardroom Alpha · Filing insights

AN2 Therapeutics, Inc. urges voting FOR all Class I nominees and FOR ratification of PwC for 2026.

About An2 Therapeutics Inc
Market cap
$147M
1Y TSR
+313.9%
3Y TSR
−13.7%
Board grade
C
Sector
Healthcare
CEO
Eric Easom
Last annual meeting: Jun 3, 2026 · View full An2 Therapeutics Inc profile →
DEFA14A

 

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a)

of the Securities Exchange Act of 1934

Filed by the Registrant Filed by a party other than the Registrant

Check the appropriate box:

Preliminary Proxy Statement

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
Definitive Proxy Statement

Definitive Additional Materials

Soliciting Material Pursuant to §240.14a-12

AN2 Therapeutics, Inc.

(Name of Registrant as Specified in Its Charter)

(Name of Person(s) Filing Proxy Statement if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

 

No fee required.

Fee paid previously with preliminary materials.

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

 

 

 

 


 

img221957288_0.jpg

P.O. BOX 8016, CARY, NC 27512-9903 Your vote matters! AN2 Therapeutics, Inc. Annual Meeting of Stockholders Wednesday, June 3, 2026 8:00 AM, Pacific Time Residence Inn, 555 Glenwood Avenue, Menlo Park, California 94025 styleINA Meeting Materials: Notice of Meeting and Proxy Statement & Annual Report on Form 10-K Important Notice Regarding the Availability of Proxy Materials for the Stockholders Meeting to be Held on June 3, 2026 for Stockholders of Record as of April 15, 2026 To order paper materials, use one of the following methods. For a convenient way to view proxy materials, vote, and obtain directions to attend the meeting, go to www.proxydocs.com/ANTX To vote your proxy while visiting this site, you will need the 12 digit control number in the box below. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting. Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the Internet. If you want to receive a paper or e-mail copy of the proxy materials, which include the Notice and Proxy Statement and Annual Report, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year's meeting, you must make this request on or before May 22, 2026. Internet: www.investorelections.com/ANTX Call: 1-866-648-8133 Email: paper@investorelections.com * If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located below) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material. Your control number Have the 12 digit control number located in the box above available when you access the website and follow the instructions. SEE REVERSE FOR FULL AGENDA Copyright © 2026 BetaNXT, Inc. or its affiliates. All Rights Reserved


 

img221957288_1.jpg

AN2 Therapeutics, Inc. Annual Meeting of Stockholders THE BOARD OF DIRECTORS RECOMMENDS A VOTE: "FOR" each of the nominees in Proposal 1 and "FOR" Proposal 2 PROPOSAL 1. To elect each of the following nominees as Class I directors until the 2029 annual meeting of stockholders or until their respective successors have been elected or appointed. 1.01 Kabeer Aziz 1.02 Gilbert Lynn Marks, M.D. 1.03 Rob Readnour, Ph.D. 2. To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. NOTE: In their discretion, Eric Easom, Lucy Day, and Josh Eizen are authorized to vote upon such other business properly brought before the Annual Meeting or any adjournments or postponements thereof.


From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from An2 Therapeutics Inc (ANTX)

Reference

Frequently asked questions

When did An2 Therapeutics Inc file this DEFA14A?
An2 Therapeutics Inc (ANTX) filed this Additional Proxy Materials (DEFA14A) with the SEC on April 22, 2026. The accession number assigned by EDGAR is 0001193125-26-170321.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
AN2 Therapeutics, Inc. urges voting FOR all Class I nominees and FOR ratification of PwC for 2026. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find An2 Therapeutics Inc's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A An2 Therapeutics Inc has filed under CIK 1880438, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer